TY - JOUR
T1 - Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck
AU - Rades, Dirk
AU - Kronemann, Stefanie
AU - Meyners, Thekla
AU - Bohlen, Guenther
AU - Tribius, Silke
AU - Kazic, Nadja
AU - Schroeder, Ursula
AU - Hakim, Samer G.
AU - Schild, Steven E.
AU - Dunst, Juergen
PY - 2011/7/15
Y1 - 2011/7/15
N2 - Purpose: To compare the outcomes of four cisplatin-based radiochemotherapy regimens in 311 patients with Stage III/IV squamous cell carcinoma of the head and neck. Methods and Materials: Concurrent chemotherapy consisted of three courses of cisplatin 100 mg/m2 on Day 1 (Group A, n = 74), two courses of cisplatin 20 mg/m2 on Days 1-5 plus 5-fluorouracil 1,000 mg/m2 on Days 1-5 (Group B, n = 49), two courses of cisplatin 20 mg/m2 on Days 1-5 plus 5-fluorouracil 600 mg/m2 on Days 1-5 (Group C, n = 102), or two courses of cisplatin 20 mg/m2 on Days 1-5 (Group D, n = 86). The groups were retrospectively compared for toxicity and outcomes, and 11 additional factors were evaluated for outcomes. Results: No significant difference was observed among the groups regarding radiation-related acute oral mucositis and radiation-related late toxicities. Acute Grade 3 skin toxicity was significantly more frequent in Group B than in the patients of the other three groups (p = .013). The chemotherapy-related Grade 3 nausea/vomiting rate was 24% for Group A, 8% for Group B, 9% for Group C, and 6% for Group D (p = .003). The corresponding Grade 3 nephrotoxicity rates were 8%, 1%, 2%, and 1% (p = .019). The corresponding Grade 3-4 hematologic toxicity rates were 35%, 41%, 19%, and 21% (p = .027). Chemotherapy could be completed in 50%, 59%, 74%, and 83% of the Group A, B, C, and D patients, respectively (p = .002). Toxicity-related radiotherapy breaks occurred in 39%, 43%, 21%, and 15% of Groups A, B, C, and D, respectively (p = .005). The 3-year locoregional control rate was 67%, 72%, 60%, and 59% for Groups A, B, C, and D, respectively (p = .48). The corresponding 3-year metastasis-free survival rates were 67%, 74%, 63%, and 79% (p = .31), and the corresponding 3-year survival rates were 60%, 63%, 50%, and 71% (p = .056). On multivariate analysis, Karnofsky performance status, histologic grade, T/N category, preradiotherapy hemoglobin level, completion of chemotherapy, and radiotherapy breaks were associated with the outcome. Conclusion: The four compared radiochemotherapy regimens were not significantly different regarding treatment outcomes. Two courses of cisplatin 20 mg/m2 on Days 1-5 were better tolerated than the other three regimens.
AB - Purpose: To compare the outcomes of four cisplatin-based radiochemotherapy regimens in 311 patients with Stage III/IV squamous cell carcinoma of the head and neck. Methods and Materials: Concurrent chemotherapy consisted of three courses of cisplatin 100 mg/m2 on Day 1 (Group A, n = 74), two courses of cisplatin 20 mg/m2 on Days 1-5 plus 5-fluorouracil 1,000 mg/m2 on Days 1-5 (Group B, n = 49), two courses of cisplatin 20 mg/m2 on Days 1-5 plus 5-fluorouracil 600 mg/m2 on Days 1-5 (Group C, n = 102), or two courses of cisplatin 20 mg/m2 on Days 1-5 (Group D, n = 86). The groups were retrospectively compared for toxicity and outcomes, and 11 additional factors were evaluated for outcomes. Results: No significant difference was observed among the groups regarding radiation-related acute oral mucositis and radiation-related late toxicities. Acute Grade 3 skin toxicity was significantly more frequent in Group B than in the patients of the other three groups (p = .013). The chemotherapy-related Grade 3 nausea/vomiting rate was 24% for Group A, 8% for Group B, 9% for Group C, and 6% for Group D (p = .003). The corresponding Grade 3 nephrotoxicity rates were 8%, 1%, 2%, and 1% (p = .019). The corresponding Grade 3-4 hematologic toxicity rates were 35%, 41%, 19%, and 21% (p = .027). Chemotherapy could be completed in 50%, 59%, 74%, and 83% of the Group A, B, C, and D patients, respectively (p = .002). Toxicity-related radiotherapy breaks occurred in 39%, 43%, 21%, and 15% of Groups A, B, C, and D, respectively (p = .005). The 3-year locoregional control rate was 67%, 72%, 60%, and 59% for Groups A, B, C, and D, respectively (p = .48). The corresponding 3-year metastasis-free survival rates were 67%, 74%, 63%, and 79% (p = .31), and the corresponding 3-year survival rates were 60%, 63%, 50%, and 71% (p = .056). On multivariate analysis, Karnofsky performance status, histologic grade, T/N category, preradiotherapy hemoglobin level, completion of chemotherapy, and radiotherapy breaks were associated with the outcome. Conclusion: The four compared radiochemotherapy regimens were not significantly different regarding treatment outcomes. Two courses of cisplatin 20 mg/m2 on Days 1-5 were better tolerated than the other three regimens.
KW - Cisplatin-based radiochemotherapy
KW - Head-and-neck cancer
KW - Toxicity
KW - Treatment outcomes
UR - http://www.scopus.com/inward/record.url?scp=79959371735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959371735&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2010.03.033
DO - 10.1016/j.ijrobp.2010.03.033
M3 - Article
C2 - 20638185
AN - SCOPUS:79959371735
SN - 0360-3016
VL - 80
SP - 1037
EP - 1044
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -